The state of Florida currently has 39 active clinical trials seeking participants for COVID19 research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
The Burden of COVID-19 Survivorship
Recruiting
This research study is being done to find out what the longer-term physiological consequences of COVID-19 are, and to determine if exercise therapy can help improve lung function, heart function and overall fitness, and reduce symptoms in people recovering from SARS-CoV-2.
Gender:
All
Ages:
Between 21 years and 75 years
Trial Updated:
03/27/2024
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Covid19
Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.
Recruiting
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of NP-101 in treating high-risk participants who have tested positive for Covid-19. The main question[s] it aims to answer are: To evaluate the safety of NP-101, as well as establish the maximum tolerated dose in high risk Covid-19 positive patients. Participants will [describe the main tasks participants will be asked to do, treatments they'll be given and use bullets if it is more than 2 items]. If there is... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/22/2024
Locations: L&A Morales Healthcare/ Enrique Villa, MD Principal Investigator, Miami, Florida
Conditions: COVID-19
Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer
Recruiting
This study evaluates immunologic response following COVID-19 vaccination in children, adolescents, and young adults with cancer. Vaccines work by stimulating the body's immune cells to respond against a specific disease. The immune response produces protection from that disease. Effects from cancer and from treatments for cancer can reduce the body's natural disease fighting ability (called immunity). Factors such as vaccine type, timing of vaccine dosing related to treatment for cancer and numb... Read More
Gender:
All
Ages:
Between 6 months and 37 years
Trial Updated:
03/14/2024
Locations: Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida +9 locations
Conditions: COVID-19 Infection, Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm
Strategies and Treatments for Respiratory Infections &; Viral Emergencies (STRIVE): Shionogi Protease Inhibitor
Recruiting
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622, an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi &; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of S-217622 when given in addition to standard of... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: University of Florida - Gainesville (Site 201-004), Gainesville, Florida +2 locations
Conditions: COVID-19
SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
Recruiting
The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Atea Study Site, Coral Gables, Florida +22 locations
Conditions: SARS CoV 2 Infection, COVID-19
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: University of Miami, Coral Gables, Florida +1 locations
Conditions: COVID-19
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
Recruiting
The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies will receive study vaccine as a shot depending on what group they are in. Substudy A design: Phase 1 includes participant... Read More
Gender:
All
Ages:
Between 6 months and 11 years
Trial Updated:
03/12/2024
Locations: Indago Research & Health Center, Inc, Hialeah, Florida +10 locations
Conditions: SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19
Recruiting
This is a randomized, double-blind, sham controlled, stratified, pivotal efficacy and safety study of the EmitBio RD-X19 treatment device in Individuals 40 Years of age and older with Mild COVID-19 in the at-home setting.
Gender:
All
Ages:
40 years and above
Trial Updated:
03/11/2024
Locations: 305 - Indago Research and Health Center, Hialeah, Florida +3 locations
Conditions: COVID-19
Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
Recruiting
Primary objective: - To evaluate the efficacy of oral reparixin versus standard care alone in limiting disease progression in adult patients hospitalised for infectious pneumonia acquired in the community (CAP), including COVID-19. Secondary objectives: - To determine the effect of reparixin on several disease severity/progression measures including recovery, ventilatory free days and mortality. Safety objectives: - To evaluate the safety of oral reparixin versus placebo in the specific cli... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/01/2024
Locations: Research Alliance Inc., Clearwater, Florida +2 locations
Conditions: Infectious Pneumonia, Severe COVID-19
A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883.
Recruiting
The purpose of the study is to learn about the safety of PF-07817883 and how PF-07817883 is processed in the body of adult participants. These participants will have different degrees of loss of liver function. Participants with mild, moderate, severe or no loss of liver function will be enrolled in 4 groups. This study is seeking participants who: are male or female of 18- 75 years of age either have different amounts of damage to liver function or for one of the groups, no damage willing to... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/01/2024
Locations: Research Centers of America ( Hollywood ), Hollywood, Florida +1 locations
Conditions: COVID-19
A Study Evaluating Tocilizumab in Pediatric Patients Hospitalized With COVID-19
Recruiting
This is a single-arm, open-label study to assess the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of tocilizumab (TCZ) for the treatment of pediatric patients from birth to less than 18 years old hospitalized with COVID-19 and who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.
Gender:
All
Ages:
17 years and below
Trial Updated:
02/29/2024
Locations: University of Florida Jacksonville, Jacksonville, Florida
Conditions: COVID-19
A Study of Baricitinib (LY3009104) in Children With COVID-19
Recruiting
The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.
Gender:
All
Ages:
Between 2 years and 18 years
Trial Updated:
02/27/2024
Locations: Arnold Palmer Hospital for Children, Orlando, Florida
Conditions: Covid19, Corona Virus Infection